Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Celldex Therapeutics
Modality
protein_peptide
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01498328CT.gov A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | — | Completed | — | — | — |
NCT01480479CT.gov Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Giant Cell Glioblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Keyhole Limpet Hemocyanin (this asset) | Celldex Therapeutics | P3 | BB · 66 |
| Irinotecan | Case Comprehensive Cancer Center | P2 | BBB |
| Cediranib | Lawrence Recht | P2 | BBB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Rindopepimut | Celldex Therapeutics | P3 | BB |
| Vorinostat | National Cancer Institute (NCI) | P2 | BB |
| Gefitinib | National Cancer Institute (NCI) | P2 | BB |
+42 more in the Giant Cell Glioblastoma cohort
Other indications for Keyhole Limpet Hemocyanin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Plasma Cell Myeloma | — | P2 | B · 62 |
| Gliosarcoma | — | P3 | B · 61 |
| Non-Hodgkin Lymphoma | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- IrinotecanCase Comprehensive Cancer CenterBBB
- CediranibLawrence RechtBBB
- TemsirolimusNational Cancer Institute (NCI)BBB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
- SorafenibNational Cancer Institute (NCI)BB
Citation
Floatz Terminal. Keyhole Limpet Hemocyanin in Giant Cell Glioblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/keyhole-limpet-hemocyanin-giant-cell-glioblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →